We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+20.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$537M
AUM Growth
+$121M
Cap. Flow
+$76M
Cap. Flow %
14.17%
Top 10 Hldgs %
39.95%
Holding
98
New
28
Increased
18
Reduced
12
Closed
34

Top Buys

1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.9M
2
XLRN
Acceleron Pharma
XLRN
+$9.49M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.34M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$9.04M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.82M

Top Sells

1
ABT icon
Abbott
ABT
+$15.4M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.1M
3
CELG
Celgene Corp
CELG
+$12.7M
4
SHPG
Shire pic
SHPG
+$12.2M
5
AERI
Aerie Pharmaceuticals
AERI
+$7.8M

Sector Composition

1 Healthcare 59.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRIX icon
51
IRIDEX
IRIX
$16.3M
$2.97M 0.55%
250,000
+50,000
+25% +$703K
ITCI
52
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.44M 0.45%
+150,000
New +$2.17M
DERM
53
DELISTED
Dermira, Inc.
DERM
$2.22M 0.41%
+65,000
New +$2.1M
CBAY
54
DELISTED
Cymabay Therapeutics
CBAY
$2.15M 0.4%
+500,000
New +$1.43M
CFMS
55
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.09M 0.39%
+16,000
New +$2.71M
PTCT icon
56
PTC Therapeutics
PTCT
$6.52B
$1.97M 0.37%
+200,000
New +$2.42M
STML
57
DELISTED
Stemline Therapeutics, Inc.
STML
$1.92M 0.36%
+225,000
New +$2.05M
FXF icon
58
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
$1.83M 0.34%
19,300
-27,100
-58% -$2.57M
ZSAN
59
DELISTED
Zosano Pharma Corporation
ZSAN
$1.79M 0.33%
+1,343
New +$1.62M
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$895K 0.17%
172,184
– –
AVEO
61
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$885K 0.16%
+150,000
New +$1.08M
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$619K 0.12%
125,000
-240,000
-66% -$2.31M
XENE icon
63
Xenon Pharmaceuticals
XENE
$6.6B
$600K 0.11%
150,000
-175,000
-54% -$1.38M
AKTX
64
Akari Therapeutics
AKTX
$19.3M
$516K 0.1%
58
– –
ABT icon
65
CALL
Abbott
ABT
$175B
– –
-200,000
Closed -$7.68M
ABT icon
66
Abbott
ABT
$175B
– –
-400,000
Closed -$15.4M
ACAD icon
67
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-350,000
Closed -$10.1M
ACRS icon
68
Aclaris Therapeutics
ACRS
$793M
– –
-120,000
Closed -$3.26M
ARCT icon
69
Arcturus Therapeutics
ARCT
$172M
– –
-71,429
Closed -$1.05M
AVDL
70
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-575,000
Closed -$5.97M
BIIB icon
71
Biogen
BIIB
$30.4B
– –
-15,000
Closed -$4.25M
BLUE
72
DELISTED
bluebird bio
BLUE
– –
-2,316
Closed -$1.85M
BMY icon
73
Bristol-Myers Squibb
BMY
$124B
– –
-100,000
Closed -$5.48M
BSX icon
74
CALL
Boston Scientific
BSX
$65.4B
– –
-300,000
Closed -$6.49M
GKOS icon
75
Glaukos
GKOS
$9.21B
– –
-200,000
Closed -$6.86M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Ghost Tree Capital held 98 positions worth $537M, up 29% from $415M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital deployed $76M of net new capital in Q1 2017, opening 28 new positions and adding to 18 existing holdings. Its largest new stake was Neurocrine Biosciences: 300,000 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Shire pic, an estimated $12.2M trimmed.

  • Ghost Tree Capital's largest Q1 2017 buy was Neurocrine Biosciences: 300,000 shares worth $13M.
  • Ghost Tree Capital added most to Acceleron Pharma in Q1 2017, an estimated $9.49M increase.
  • Ghost Tree Capital's biggest Q1 2017 reduction was Shire pic, cutting an estimated $12.2M.
  • Ghost Tree Capital fully exited Abbott in Q1 2017, selling an estimated $15.4M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $537M portfolio in Q1 2017.
  • Ghost Tree Capital opened 28 new positions and closed 34 in Q1 2017.
  • Ghost Tree Capital's portfolio value rose 29% quarter-over-quarter to $537M.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.